研報掘金丨華鑫證券:首予誠益通“買入”評級 腦機接口布局持續推進
華鑫證券日前研報指出,誠益通業績符合預期,下遊客戶短期需求變化對業績產生擾動。公司通過侵入式和非侵入式腦機接口技術的戰略佈局顯著提升其在全球康復醫療器械市場的競爭力,並持續推動技術創新和產業化進程。公司通過強化技術賦能、精準的市場佈局和內外部管理優化,在智能製造和康復醫療設備兩個板塊持續推動業績增長。公司產品已應用於國內5000餘家醫療機構,業務範圍覆蓋30多個國家主流市場。公司深耕康復領域,與腦機接口技術結合有望實現康復設備技術的跨越式突破,進而帶動業績增長,首次覆蓋,給予“買入”投資評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.